The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience. Issue 7 (July 2019) - Sim, V.; Forner, S.; Burcombe, R.; Glendenning, J.